U.S. markets closed

Otonomy, Inc. (OTIC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
4.5000+0.2000 (+4.65%)
At close: 1:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
Previous Close4.3000
Open4.2900
Bid4.5400 x 2900
Ask4.5800 x 800
Day's Range4.2600 - 4.6300
52 Week Range1.5300 - 4.8900
Volume162,780
Avg. Volume267,612
Market Cap217.025M
Beta (5Y Monthly)2.16
PE Ratio (TTM)N/A
EPS (TTM)-1.2700
Earnings DateNov 04, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Otonomy to Participate in Two Upcoming Investor Conferences
      GlobeNewswire

      Otonomy to Participate in Two Upcoming Investor Conferences

      SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that management is scheduled to participate in two upcoming virtual investor conferences. * Evercore ISI 3rd Annual HealthCONx Conference: presentation on December 1, 2020 at 3:05 p.m. ET / 12:05 p.m. PT. A live audio webcast of the presentation will be available through the Events page of the company’s website at www.otonomy.com and an archived replay will be available shortly after the event. * Piper Sandler 32nd Annual Healthcare Conference: 1 on 1 investor meetings on December 2, 2020. A pre-recorded fireside chat will be accessible from November 23 to December 3, 2020 through the Events page of the company’s website at www.otonomy.com. About Otonomy Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss, and tinnitus. For additional information please visit www.otonomy.com.Contacts:Media Inquiries Spectrum Science Chloé-Anne Ramsey Vice President 404.865.3601 cramsey@spectrumscience.comInvestor Inquiries Westwicke ICR Robert H. Uhl Managing Director 858.356.5932 robert.uhl@westwicke.com

    • Otonomy, Inc. (NASDAQ:OTIC) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
      Simply Wall St.

      Otonomy, Inc. (NASDAQ:OTIC) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates

      It's been a good week for Otonomy, Inc. (NASDAQ:OTIC) shareholders, because the company has just released its latest...

    • Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates
      Zacks

      Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates

      Otonomy (OTIC) delivered earnings and revenue surprises of 12.00% and -54.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?